Newly reported from EULAR 2024: Higher Step Count Lowers Risk of Developing RA by 45%

Newly reported from EULAR 2024: Higher Step Count Lowers Risk of Developing RA by 45% A higher daily step count was linked to a lower risk of developing rheumatoid arthritis (RA), according to a prospective cohort study presented at the 2024 European Congress of Rheumatology (EULAR). The benefits of incremental increases (1000 steps per day) were particularly notable […]

Newscasting from EULAR 2024: Analysis Demonstrates Long-Term Safety Profile of Filgotinib for RA Treatment

Newscasting from EULAR 2024: Analysis Demonstrates Long-Term Safety Profile of Filgotinib for RA Treatment The safety profile of filgotinib remained stable more than 4 years among a cohort of patients with moderate to severe rheumatoid arthritis (RA), according to an updated integrated safety analysis presented at the 2024 European Congress of Rheumatology (EULAR). These results were comparable to […]

News Coverage from EULAR 2024: Abiprubart Reduces Disease Activity in Refractory Rheumatoid Arthritis

News Coverage from EULAR 2024: Abiprubart Reduces Disease Activity in Refractory Rheumatoid Arthritis Abiprubart (KPL-404) demonstrated improvements in disease activity in patients with refractory rheumatoid arthritis (RA), compared with placebo, according to new Phase 2 data presented at the 2024 European Congress of Rheumatology (EULAR). These findings showed statistically significant reduction in the Disease Activity Score […]

Directly from EULAR 2024: 8 out of 10 Patients with RA Achieve Sustained Remission at Month 12 with Upadacitinib

Directly from EULAR 2024: 8 out of 10 Patients with RA Achieve Sustained Remission at Month 12 with Upadacitinib In real-world practice, >79% of patients with moderate to severe rheumatoid arthritis (RA)were able to achieve Disease Activity Score-28 for Rheumatoid Arthritis with C-reactive protein (DAS28-CRP) remission by 6 months, which was maintained through month 12, according […]

Newly reported from EULAR 2024: Mood Disorders Worse in RA Patients with Fibromyalgia

Newly reported from EULAR 2024: Mood Disorders Worse in RA Patients with Fibromyalgia A new study found patients with rheumatoid arthritis (RA) and fibromyalgia have greater levels of disease activity and more severe mood disorders than patients with only RA. Conversely, a correlation analysis found a positive correlation between mood disorders and disease activity in patients with RA—but not with […]

News Coverage from EULAR 2024: Filgotinib Demonstrates Early, Durable PRO Improvements in RA

News Coverage from EULAR 2024: Filgotinib Demonstrates Early, Durable PRO Improvements in RA Patients with rheumatoid arthritis (RA)receiving filgotinib had meaningful improvements in patient-reported outcomes (PROs), including pain and fatigue, which occurred early and were maintained over time, according to a post hoc analysis presented at the 2024 European Congress of Rheumatology (EULAR). “The quality of life […]

Broadcasted from EULAR 2024: Total Fish Intake in Pregnancy Could Alter Risk of Juvenile Arthritis in Offspring

Broadcasted from EULAR 2024: Total Fish Intake in Pregnancy Could Alter Risk of Juvenile Arthritis in Offspring Data from a study presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress suggests increased intake of fish, whether oily or lean, was associated with an elevated risk of offspring with juvenile idiopathic arthritis (JIA). An analysis of […]

News Coverage from EULAR 2024: FIRST Questionnaire Can Help Detect Fibromyalgia in RA Patients

News Coverage from EULAR 2024: FIRST Questionnaire Can Help Detect Fibromyalgia in RA Patients A diagnosis of fibromyalgia was associated with a negative impact on the evolution of rheumatoid arthritis (RA), leading investigators of a recent study to call for a greater emphasis on optimal screening strategies. Results of the study, which were presented at the Annual European Congress […]

Newly reported from EULAR 2024 – Brian LaMoreaux, MD: Defining and Achieving Remission in Gout with Pegloticase

Newly reported from EULAR 2024 – Brian LaMoreaux, MD: Defining and Achieving Remission in Gout with Pegloticase The MIROR program was originally developed to test the idea that concomitant methotrexate and pegloticase therapy could prevent the development of anti-drug antibodies, which often limit the treatment’s effectiveness. The results were very successful. Patients with gout receiving methotrexate had […]